Category: Drug Safety Alerts
-
Long-Term Use Of Heartburn Drugs And Acid Reflux Medicines Like Prevacid, Prilosec, and Nexium May Be Linked To Strokes
The Proton Pump Inhibitors (PPIs) Class Of Drugs Has Long Been Associated With Some Serious Kidney-Related Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) There has long been medical evidence — albeit…
-
Risk of Hepatitis B Reactivation Associated With Gleevec, Iclusig, And Other BCR-ABL Tyrosine Kinase Inhibitors, According To Health Canada
While Mechanism And Frequency Currently Unknown, This Situation Can Involve Acute Hepatic Failure Or Fulminant Hepatitis Leading To Liver Transplantation Or Death (Posted by Tom Lamb at DrugInjuryWatch.com) Back in May 2016…
-
Harvoni, Sovaldi, Viekira Pak, And Other Direct-Acting Antivirals Get Black-Box Warning: Risk Of Hepatitis B Virus Reactivation
October 2016 FDA Drug Safety Communication Warns About These Relatively New Drugs Which Are Increasingly Popular For Treating Chronic Hepatitis C (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: “New Safety Issue:…
-
Savaysa Label Change In September 2016 Points Out There Is No Established Way To Reverse Its Anticoagulant Effects
Use Of Prothrombin Complex Concentrates (PCC) Or Other Procoagulant Reversal Agents Have Not Been Evaluated In Clinical Outcome Studies (Posted by Tom Lamb at DrugInjuryWatch.com) In relevant part, from a September 15, 2016…
-
The Essure Birth Control Product: Safety, Regulatory, And Legal Developments Over The Past Several Months
Increasing Number Of Women Who Have Allegedly Been Harmed By The Essure Inserts Have Filed Lawsuits Against Bayer (Posted by Tom Lamb at DrugInjuryWatch.com) Bayer’s Essure® product is a permanent birth control…
-
FDA Mandates Label Change Warning About Fatal Cases Of Ketoacidosis For All Diabetes Drugs Known As Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors
This Class Of (Heavily Advertised) Drugs Includes Farxiga, Invokana, And Jardiance, Which Also Are Linked To Kidney Failure And Heart Attacks Or Myocardial Infarction (Posted by Tom Lamb at DrugInjuryWatch.com) In an…
-
Xarelto / Savaysa / Eliquis: Antidote Drug AndexXa Is Rejected By FDA In August 2016, Surprising Many Pharma Industry Observers (And Doctors?)
Portola, Which Developed AndexXa, Estimates 100,000 Patients Per Year Suffer From Severe Uncontrollable Bleeding Events That Could Require Such An Antidote (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-August 2016 the US…
-
Denosumab Drugs Prolia And Xgeva Linked To QT Interval Prolongation Associated With Hypocalcemia
Australia's Drug Regulator Issues Warnings And Mandates Label Changes, Following Similar Action In Europe; Will FDA Follow Thess Leads? (Posted by Tom Lamb at DrugInjuryWatch.com) In early August 2016 we learned about…
-
Invokana / Farxiga / Jardiance: Urinary Tract Infections Leading To Urosepsis And Pyelonephritis Are Lesser Known Side Effects
To Date, More Attention Paid To The Association Between These Sodium-Glucose Cotransporter-2 Inhibitors And Diabetic Ketoacidosis Or Acute Kidney Injury (Posted by Tom Lamb at DrugInjuryWatch.com) Over the past year the FDA…
-
Summer 2016 Update On Diabetes Medicines Invokana / Farxiga / Jardiance: Drug Label Changes And Safety Investigations
According To Drug Regulators, New Possible Side Effects Include: Fatal Cases Of Ketoacidosis; Leg, Foot, And Toe Amputations; And, Lactic Acidosis (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Invokana “Black-Box Warning” For…